KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Payables (2017 - 2025)

Historic Payables for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $15.8 million.

  • Bionano Genomics' Payables fell 3313.74% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 3313.74%. This contributed to the annual value of $27.3 million for FY2024, which is 6592.47% down from last year.
  • Latest data reveals that Bionano Genomics reported Payables of $15.8 million as of Q3 2025, which was down 3313.74% from $18.0 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Payables ranged from a high of $80.2 million in Q4 2023 and a low of $2.2 million during Q1 2021
  • Its 5-year average for Payables is $18.7 million, with a median of $15.4 million in 2023.
  • Per our database at Business Quant, Bionano Genomics' Payables surged by 53975.59% in 2023 and then crashed by 6592.47% in 2024.
  • Over the past 5 years, Bionano Genomics' Payables (Quarter) stood at $10.8 million in 2021, then grew by 16.39% to $12.5 million in 2022, then soared by 539.76% to $80.2 million in 2023, then crashed by 65.92% to $27.3 million in 2024, then tumbled by 42.12% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q3 2025, $18.0 million for Q2 2025, and $19.6 million during Q1 2025.